Inventor · disambiguated record
Ted Yednock
Also filed as: YEDNOCK TED · YEDNOCK TED A
10 granted patents·19 pending applications·779 citations·filing 1989–2024
92Inventor score
Top patents by PatentIndex Score
29 records- 0197US5840299AHumanized antibodies against leukocyte adhesion molecule VLA-4ATHENA NEUROSCIENCES INC·Filed 1995·Granted Nov 24, 1998·323 cites·29 claims
- 0295US5098833ADNA sequence encoding a functional domain of a lymphocyte homing receptorGENENTECH INC·Filed 1989·Granted Mar 24, 1992·214 cites·33 claims
- 0394US8246958B2Methods of inhibiting alpha-4-dependent interactions with VCAM-1 with anti-VLA-4 antibodiesBENDIG MARY M·Filed 2008·Granted Aug 21, 2012·56 cites·9 claims
- 0492US10723788B2Anti-complement factor C1q Fab fragments and uses thereofANNEXON INC·Filed 2016·Granted Jul 28, 2020·6 cites·20 claims
- 0592US5216131ALymphocyte homing receptorsGENENTECH INC·Filed 1991·Granted Jun 1, 1993·106 cites·16 claims
- 0690US11999779B2Anti-complement factor C1q Fab fragments and uses thereofANNEXON INC·Filed 2020·Granted Jun 4, 2024·2 cites·19 claims
- 0784US7435802B2Humanized anti-VLA4 immunoglobulinsELAN PHARACEUTICALS INC·Filed 2004·Granted Oct 14, 2008·21 cites·1 claims
- 0882US2025002567A1Anti-complement factor c1q fab fragments and uses thereofANNEXON INC·Filed 2024·Application pending·0 cites
- 0980US7576101B2Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agentsELAN PHARM INC·Filed 2004·Granted Aug 18, 2009·13 cites·26 claims
- 1079US5318890AAssays for inhibitors of leukocyte adhesionUNIV CALIFORNIA·Filed 1991·Granted Jun 7, 1994·38 cites·16 claims
- 1167US2024083989A1Compositions and methods for treating brain injuryANNEXON INC·Filed 2023·Application pending·0 cites
- 1264US2025313614A1Compositions and methods for treating ocular diseasesANNEXON INC·Filed 2023·Application pending·0 cites
- 1362US2015064177A1Therapeutic uses of humanized antibodies against alpha-4 integrinBIOGEN IDEC INC·Filed 2014·Application pending·0 cites
- 1460US12486322B2Anti-complement factor C1q antibodies with single binding arms and uses thereofANNEXON INC·Filed 2022·Granted Dec 2, 2025·0 cites·12 claims
- 1560US2025074973A1Compositions and methods for treating huntington’s diseaseANNEXON INC·Filed 2022·Application pending·0 cites
- 1660US2025313615A1Compositions and methods for treating lupus nephritisANNEXON INC·Filed 2023·Application pending·0 cites
- 1759US2008279873A1Active immunization to generate antibodies to soluble a-betaSEUBERT PETER A·Filed 2008·Application pending·0 cites
- 1859US2004171815A1Humanized antibodies that recognize beta amyloid peptideFiled 2003·Application pending·0 cites
- 1958US2024059765A1Compositions and methods for treating ocular diseasesANNEXON INC·Filed 2021·Application pending·0 cites
- 2056US2006229435A1Lymphocyte homing receptorsGENENTECH INC·Filed 2006·Application pending·0 cites
- 2154US2013059337A1Therapeutic Uses of Humanized Antibodies Against ALPHA-4 IntegrinBENDIG MARY M·Filed 2012·Application pending·0 cites
- 2253US2004213800A1Active immunization to generate antibodies to soluble A-betaFiled 2004·Application pending·0 cites
- 2353US2006188512A1Active immunization to generate antibodies to solble a-betaYEDNOCK TED·Filed 2004·Application pending·0 cites
- 2452US2023391858A1Compositions and methods for treating blood disordersANNEXON INC·Filed 2021·Application pending·0 cites
- 2549US2024034775A1Compositions and methods for treating epilepsyTHE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADS·Filed 2021·Application pending·0 cites
- 2649US2024109957A1Compositions and methods for treating blood disordersANNEXON INC·Filed 2020·Application pending·0 cites
- 2747US2020140533A1Compositions and methods for treating brain injuryANNEXON INC·Filed 2019·Application pending·0 cites
- 2841US2019151414A1Anti-complement factor c4/c4b antibodies and uses thereofANNEXON INC·Filed 2017·Application pending·0 cites
- 2938US2019161535A1Compositions and methods for treating spinal muscular atrophyANNEXON INC·Filed 2017·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →